#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasiiiigton,	D.C.	2054

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CROOKE STANLEY T</u>						2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ ISIS ]								(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner				
(Last) (First) (Middle) 2292 FARADAY AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 01/14/2004									bel	icer (give title ow) Chairman, P	Other below President, CEO	′	
(Street) CARLSI (City)		A tate)	92008 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									) <mark>K</mark> Fo Fo	ral or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Tal	ole I - No	n-Deriv	ative	Sec	uritie	s Acc	quired,	Dis	posed o	f, or	Ben	eficial	y Owi	ned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		Transaction Disposed Code (Instr.		ties Acquired (A) o l Of (D) (Instr. 3, 4 a			and 5) Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership					
							Code	v	Amount (A		) or )	Price	Tran	orted saction(s) r. 3 and 4)		(Instr. 4)			
Common	Stock			01/14/	2004	0	1/14/2	2004	S <sup>(1)</sup>		5,000(1)		D	\$7.50	)	967,241 D			
Common	Stock			01/15/	2004	0	1/15/2	2004	S <sup>(1)</sup>		5,500(1)		D	\$7.544	15 961,741 D				
Common	Stock			01/16/	2004	0	1/16/2	2004	S <sup>(1)</sup>		2,000(1)		D	\$7.502	025 959,741 D				
		7	Table II -								sed of, onvertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, irity or Exercise (Month/Day/Year) if any		on Date,	4. Transar Code (I 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiratio		ee ear)	Amount of Securities Underlying Derivative Security (Instr. and 4)		str. 3	Price of erivative ecurity nstr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

### Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10-6-03.

#### Remarks:

B. Lynne Parshall, by Power of Attorney 01/16/2004

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.